KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal Antibody in Severe Asthma
16:00 EDT 11 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in
a randomized, double-blind, placebo-controlled Phase 2 clinical trial of
KB003, the company’s anti-GM-CSF Humaneered™ monoclonal antibody, in
subjects w...
Other Sources for this Article
KaloBios Pharmaceuticals, Inc.
Jeffrey H. Cooper
Chief
Financial Officer
650-243-3100
or
Media:
Kureczka/Martin
Associates
Joan E. Kureczka
415-821-2413
Joan@Kureczka-Martin.com
More From BioPortfolio on "KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal Antibody in Severe Asthma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
